Do investigational MET inhibitors have potential for the treatment of gastric cancer?

被引：2
|
作者：
Athauda, Avani [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Downs Rd, Sutton, Surrey, England
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2019年 / 28卷 / 04期
关键词：
MET; gastric cancer; biomarkers; receptor tyrosine kinase MET; GENE COPY NUMBER; DOUBLE-BLIND; AMPLIFICATION; ADENOCARCINOMA; RESISTANCE; EXPRESSION; SURVIVAL; THERAPY; CAPECITABINE; COMBINATION;
D O I：
10.1080/13543784.2019.1582641
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：299 / 302
页数：4
相关论文
共 50 条
  • [41] Farnesyltransferase inhibitors - Potential role in the treatment of cancer
    Cox, AD
    DRUGS, 2001, 61 (06) : 723 - 732
  • [42] Investigational BACE inhibitors for the treatment of Alzheimer's disease
    Imbimbo, Bruno P.
    Watling, Mark
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (11) : 967 - 975
  • [43] Early investigational tubulin inhibitors as novel cancer therapeutics
    Nepali, Kunal
    Ojha, Ritu
    Lee, Hsueh-Yun
    Liou, Jing-Ping
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (08) : 917 - 936
  • [44] Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
    Yohei Funakoshi
    Toru Mukohara
    Hideo Tomioka
    Roudy Chiminch Ekyalongo
    Yu Kataoka
    Yumiko Inui
    Yuriko Kawamori
    Masanori Toyoda
    Naomi Kiyota
    Yutaka Fujiwara
    Hironobu Minami
    Investigational New Drugs, 2013, 31 : 1158 - 1168
  • [45] Excessive MET Signaling Causes Acquired Resistance to and Addiction to MET Inhibitors in MKN45 Gastric Cancer Cell Line
    Funakoshi, Y.
    Mukohara, T.
    Tomioka, H.
    Ekyalongo, R. C.
    Kataoka, Y.
    Inui, Y.
    Kawamori, Y.
    Kiyota, N.
    Fujiwara, Y.
    Minami, H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 93 - 94
  • [46] Clinical significance of MET in gastric cancer
    Mikito Inokuchi
    Sho Otsuki
    Yoshitaka Fujimori
    Yuya Sato
    Masatoshi Nakagawa
    Kazuyuki Kojima
    World Journal of Gastrointestinal Oncology, 2015, 7 (11) : 317 - 327
  • [47] Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
    Funakoshi, Yohei
    Mukohara, Toru
    Tomioka, Hideo
    Ekyalongo, Roudy Chiminch
    Kataoka, Yu
    Inui, Yumiko
    Kawamori, Yuriko
    Toyoda, Masanori
    Kiyota, Naomi
    Fujiwara, Yutaka
    Minami, Hironobu
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1158 - 1168
  • [48] MET inhibitors in cancer: pitfalls and challenges
    Oliveres, Helena
    Pineda, Estela
    Maurel, Joan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (01) : 73 - 85
  • [49] Clinical significance of MET in gastric cancer
    Inokuchi, Mikito
    Otsuki, Sho
    Fujimori, Yoshitaka
    Sato, Yuya
    Nakagawa, Masatoshi
    Kojima, Kazuyuki
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (11) : 317 - 327
  • [50] MET-inhibitors meet MET mutations in lung cancer
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1248 - S1254
12345